UnicoCell, a developer of allogeneic stem cell-based therapies, is set to hold a pre-listing performance briefing today and is expected to list on the Innovation Board in May. Chairman Yi-Wen Tsai stated that UnicoCell has focused on allogeneic stem cell research and development from the outset. Currently, its stem cell-based therapy ELIXCYTE targets two indications: knee osteoarthritis in Phase III enrollment and Stage 1/2 chronic kidney disease in end-of-study review.
Yi-Wen Tsai emphasized that UnicoCell focuses on addressing medical needs related to stem cells and aging. Given the global trend of aging populations, the indications for UnicoCell's therapies have substantial market demand worldwide. All clinical trials have received approvals and supervision from the Taiwan Food and Drug Administration (TFDA) and the United States Food and Drug Administration (FDA).
Yi-Wen Tsai pointed out that UnicoCell's primary focus on allogeneic stem cell research and development has led to the advancement of ELIXCYTE, which targets two indications currently undergoing clinical trials: knee osteoarthritis in Phase III enrollment and Stage 1/2 chronic kidney disease in end-of-study review.
General Manager Yi-Pei Hung stated that the Phase III trials for knee osteoarthritis received approvals from the TFDA and FDA in February and March 2023, respectively. Enrollment commenced in Taiwan in 2023, with an expected enrollment of 165 participants. UnicoCell aims to complete Phase III trials by 2026 and apply for drug approval after the end-of-study review.
Yi-Pei Hung mentioned that UnicoCell has established a cell preparation factory compliant with PIC/S GMP standards. The company plans to apply for certification within a year and has implemented stringent quality control measures from selecting cells from young and healthy donors to establishing laboratory quality systems that have passed multiple domestic and international audits. This infrastructure supports the entire process of allogeneic stem cell therapy development, from raw materials to clinical trials to drug production.
UnicoCell has also expanded its application of stem cell technology by successfully developing stem cell-derived exosomes with a high concentration patented process. These exosomes have obtained FDA master file registration and International Nomenclature of Cosmetic Ingredients (INCI) certification, and have been sold to Japan as raw materials for cosmetics. Additionally, UnicoCell collaborates with hospital ophthalmology departments to develop drugs for treating degenerative retinal diseases. Relevant preclinical trials have been completed.
UnicoCell's self-developed ultra-low-temperature drug container, UnicoVial, has obtained Taiwan's Class II medical device license, making it one of the few cell containers worldwide to receive medical device approval. Since the cell therapy industry still primarily uses research-type containers rather than medical device-type containers, UnicoVial's compliance with regulatory requirements ensures container safety and enhances the final stage of development in the cell therapy industry.
Regarding overseas markets, Yi-Pei Hung emphasized that for ELIXCYTE therapies targeting knee osteoarthritis and chronic kidney disease, UnicoCell plans to seek local drug approvals through licensing partnerships to establish global sales channels and generate royalty income. Both indications have markets exceeding billions of dollars globally.
Resource (mandarin):
